RNS Number:5399T
Proteome Sciences PLC
22 December 2003


                      Proteome Sciences Plc ("the Company")
                                        
                                        
                            Directors' Shareholdings



Christopher D J Pearce, a director of the Company, today informed the Company
that on 19 December 2003 he exercised options over 888,889 ordinary shares of 1p
each in the Company ("Ordinary Shares") at a price of 45p each. Following this
transaction, Mr Pearce holds options over a further 2,789,292 Ordinary Shares.


Mr Pearce also notified the Company today that on 19 December 2003 his wife sold
250,000 Ordinary Shares at 220p per share, representing 0.21 per cent. of the
Company's issued share capital. The Ordinary Shares have been sold in order to
satisfy the costs of the option exercise. Following this notification, Mr Pearce
has increased his beneficial interest in the Company by 638,889 Ordinary Shares,
an increase of 14.8 per cent., to 4,962,111 Ordinary Shares, which represents
4.12 per cent. of the issued ordinary share capital of the Company.


James L Malthouse, also a director of the Company, today informed the Company
that on 19 December 2003 he exercised options over 577,778 Ordinary Shares at a
price of 45p each. Following this transaction, Mr Malthouse holds options over a
further 1,346,650 Ordinary Shares.


Mr Malthouse also notified the Company today that on 19 December 2003 he sold
327,778 Ordinary Shares at 220p per share, representing 0.27 per cent. of the
Company's issued share capital. These Ordinary Shares have been sold in part to
satisfy the cost of the option exercise. In addition, Mr Malthouse today
notified the Company that on 19 December 2003 his wife sold 180,937 Ordinary
Shares at 220p per share, representing 0.15 per cent. of the Company's issued
share capital. Following this notification, Mr Malthouse has increased his
beneficial interest in the Company by 69,063 Ordinary Shares, an increase of
38.2 per cent., to 250,000 Ordinary Shares, which represents 0.21 per cent. of
the issued ordinary share capital of the Company.


Application has been made for the 1,466,667 Ordinary Shares to be admitted to
trading on AIM and dealings are expected to commence on 24 November 2003.



22 December 2003



For further information


Christopher Pearce, Proteome Sciences Plc                 01932 865 065

James Malthouse, Proteome Sciences Plc







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSPUGPGPUPWGGP